【摘要】 目的:比较普伐他汀与辛伐他汀降低低密度脂蛋白胆固醇(LDL-C)和升高高密度脂蛋白胆固醇(HDL-C)的临床疗效,并观察其安全性。方法:66例高胆固醇血症患者随机分为2组,各33例,每晚分别服用普伐他汀40mg或辛伐他汀40mg,连续6周。所有患者均在入选时和服药后6周抽血检查血脂,主要指标是LDL-C相对于基线值的变化,次要指标是HDL-C。安全性的评价依据实验室检查结果和临床记录的副反应。结果:普伐他汀与辛伐他汀均能明显降低LDL-C,治疗前、后比较差异有统计学意义(P<0.05);均可轻度升高HDL-C,治疗前、后比较差异无统计学意义(P>0.05)。2药的副作用均较少。结论:普伐他汀与辛伐他汀的调脂作用相当,均具有很好的耐受性。更多还原

【Abstract】 OBJECTIVE: To evaluate the efficacy and safety of Pravastatin versus Simvastatin in downregulating low density lipoprotein cholesterol(LDL-C) and upregulating high density lipoprotein cholesterol(HDL-C).METHODS: A total of 66 patients with hypercholesterolemia were enrolled: 33 were randomly assigned to receive Pravastatin(40 mg) for 6 weeks,and another 33 to receive Simvastatin(40 mg) for 6 weeks.Serum lipid levels at baseline and 6 weeks after medication were measured.The primary effective indicator was LDL-C as compared with baseline value and the secondary effective indicator was HDL-C.Safety was evaluated based on laboratory data and clinical adverse reactions.RESULTS: Both Pravastatin and Simvastatin significantly decreased LDL-C level,showing significant differences as compared with before medication(P<0.05),and HDL-C was slightly increased by either Pravastatin or Simvastatin,but the difference was not significant(P>0.05).Less adverse drug reactions were noted in both groups.CONCLUSION: Pravastatin and Simvastatin were equivalent in lipid-regulatory effect and both were well-tolerated.更多还原